Physician Assistant Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sarah Dooley

Neurology Centerville, OH Physician Assistant

NPI 1699911586 CMS profile 1151937

1975 Miamisburg Centerville Rd, Centerville, OH 45459

Open in the dashboard

General payments

$15,405

809 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Dooley of Centerville, OH is reported in the CMS Open Payments database as having received $15,405 across 809 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,825 131
2024 General $3,631 153
2023 General $2,679 138
2022 General $3,104 186
2021 General $3,113 198
2020 General $36 2
2019 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Dooley
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Sarah Dooley were reported at $2,825. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Sarah Dooley Neurology median Middle half National median
2019 $17 $474 $118–$2,177 $163
2020 $36 $367 $82–$2,309 $114
2021 $3,113 $438 $104–$2,547 $132
2022 $3,104 $442 $103–$2,388 $149
2023 $2,679 $464 $119–$2,312 $160
2024 $3,631 $468 $119–$2,323 $164
2025 $2,825 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,432 133 payments
  2. EMD Serono, Inc. $1,261 43 payments
  3. US WorldMeds, LLC $1,040 36 payments
  4. Novartis Pharmaceuticals Corporation $865 59 payments
  5. Biogen, Inc. $651 34 payments
  6. UCB, Inc. $617 42 payments
  7. Lilly USA, LLC $588 37 payments
  8. Teva Pharmaceuticals USA, Inc. $537 27 payments
  9. Neurocrine Biosciences, Inc. $533 27 payments
  10. Pfizer Inc. $518 35 payments
  11. Other $6,362 336 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,071 805 payments
  2. Education $333 4 payments
Products named General payments · program years 2019–2025
  1. QULIPTA $1,082 57 payments
  2. UBRELVY $805 50 payments
  3. BOTOX $801 42 payments
  4. Gocovri $684 14 payments
  5. INGREZZA $533 27 payments
  6. KESIMPTA $468 40 payments
  7. NURTEC ODT Primary Care $463 31 payments
  8. Briviact $457 34 payments
  9. NURTEC ODT Pain $396 27 payments
  10. AIMOVIG $390 31 payments
  11. Other $9,201 507 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

2,674

Median for Physician Assistant: 241

Drug cost

$544,967

Median for Physician Assistant: $4,110

Branded share of claims

18.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 23 $180,598
Copaxone Glatiramer Acetate Brand 13 $75,816
Rytary Carbidopa/Levodopa Brand 20 $32,618
Nuedexta Dextromethorphan Hbr/Quinidine Brand 20 $31,042
Qulipta Atogepant Brand 26 $30,981
Nurtec Odt Rimegepant Sulfate Brand 20 $30,951
Emgality Pen Galcanezumab-Gnlm Brand 34 $27,395
Ubrelvy Ubrogepant Brand 20 $21,081
Rasagiline Mesylate Generic 37 $14,876
Ajovy Autoinjector Fremanezumab-Vfrm Brand 11 $12,163

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$36,448

Medicare's payments for the services billed

Medicare patients

301

Average age 73

Services billed

564

174 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 48%
Depression 35%
Diabetes 28%
Alzheimer's or dementia 25%
Ischemic heart disease 23%
Chronic kidney disease 22%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
$666 — —
BOTOX
$252 — —
QULIPTA
$252 26 —
UBRELVY
$225 20 —
INGREZZA
$185 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

809 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record